RichardErnestChaissonMD

Infectious Disease • Baltimore, MD

Professor of Medicine, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Chaisson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chaisson's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-1725

Fax+1 410-955-0740

Education & Training

University of California (San Francisco)Fellowship, Infectious Disease, 1985 - 1987
University of California (San Francisco)Residency, Internal Medicine, 1982 - 1985
University of Massachusetts Medical SchoolClass of 1982

Certifications & Licensure

MD State Medical License 1988 - 2026
CA State Medical License 1983 - 1988
American Board of Internal Medicine Internal Medicine

Clinical Trials

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
Completed
Not Applicable
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
Completed
Phase 2
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
Completed
Phase 2
Tuberculosis Prevention for HIV Infected Adults Start of enrollment: 2002 Sep 01
Completed
Phase 3
Helping HIV Infected Patients in South Africa Adhere to Drug Regimens Start of enrollment: 2005 Feb 01
Terminated
Phase 2
Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis Start of enrollment: 2004 Oct 01
Completed
Phase 2
TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy) Start of enrollment: 2005 Jun 01
Completed
Phase 4
TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment Start of enrollment: 2003 Jul 01
Completed
Phase 2
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment Start of enrollment: 2006 Feb 01
Completed
Phase 2
A Cluster-Randomized Trial of DOTS vs DOTS Plus Active Case Finding Start of enrollment: 2007 Jul 10
Completed
Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV) Start of enrollment: 2007 Sep 01
Completed
Not Applicable
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) Start of enrollment: 2012 May 23
Completed
Phase 3
Chepetsa TB - Reducing TB Among HIV-Infected Malawians Start of enrollment: 2012 Sep 01
Completed
Not Applicable
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens Start of enrollment: 2016 Jan 25
Completed
Phase 3
Screening for TB in Pregnancy. on HIV-Infected Pregnant Women Start of enrollment: 2015 May 01
Completed
Not Applicable
Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases Start of enrollment: 2015 Oct 01
Completed
Not Applicable
Statin Adjunctive Therapy for TB Start of enrollment: 2020 Mar 09
Completed
Phase 2
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis Start of enrollment: 2020 Feb 21
Completed
Phase 2
Ultra Curto (Ultra Short) TB Prevention Therapy Start of enrollment: 2022 Mar 24
Active, not recruiting
Phase 4
Roles: Principal Investigator, Contact
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients Start of enrollment: 2023 Jul 19
Recruiting
Phase 4
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1903 citations
Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a c...
Daniel D Murray, Kazuo Suzuki, Matthew Law, Jonel Trebicka, Jacquie Neuhaus
Plos One. 2015-10-14
616 citations
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling, M. Elsa Villarino, Andrey S. Borisov, Nong Shang, Fred M. Gordin
The New England Journal of Medicine. 2011-12-07
37 citations
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial
Kelly E. Dooley, Radojkam Savic, Akshay Gupte, Mark A. Marzinke, Nan Zhang
The Lancet. HIV. 2020-06-01

Journal Articles

Screening for Tuberculosis with Xpert MTB/RIF Versus Fluorescent Microscopy Among Adults Newly Diagnosed with HIV in Rural Malawi: A Cluster Randomized Trial (CHEPETSA)
Richard E Chaisson, David W Dowdy, Clinical Infectious Diseases

Lectures

23rd Annual Clinical Care of the Patient with HIV Infection
The Johns Hopkins University School of Medicine, Baltimore, Maryland - 3/18/2013

Press Mentions

Johns Hopkins Medicine-Led Consortium to Receive up to $200 Million to Fight TB GloballyAugust 17th, 2022
40 Years Ago, the First Cases of AIDS Were Reported in the USJune 5th, 2021
40 Years Ago, the First Cases of AIDS Were Reported in the USJune 5th, 2021
Join now to see all

Grant Support

SMART4TBUSAID2022–2027
The Johns Hopkins Center For AIDS Research (Jhu Cfar)National Institute Of Allergy And Infectious Diseases2012
Administrative CoreNational Institute Of Allergy And Infectious Diseases2012
Impact Of A New Molecular TB Test On TB/HIV Outcomes Among Hiv-Infected MalawiansNational Institute Of Allergy And Infectious Diseases2011–2012
Impact Of TB On Outcome Of HIV In Pregnant WomenEunice Kennedy Shriver National Institute Of Child Health &Human Development2010–2011
Longitudinal Study Of Hiv-Associated Lung Infections In SowetoNational Heart, Lung, And Blood Institute2007–2011
Innovative Approaches For TB Control In BrazilFogarty International Center2005–2011
Innovative Approaches For Tuberculosis Control In BrazilFogarty International Center2007–2009
Innovative Approaches To Tuberculosis ControlNational Institute Of Allergy And Infectious Diseases1999–2009
Clinical Research In TuberculosisNational Institute Of Allergy And Infectious Diseases1999–2009
Dot-Haart For Hiv-Infected South African AdultsNational Institute Of Allergy And Infectious Diseases2003–2008
Novel TB Prevention Regimens For Hiv-Infected AdultsNational Institute Of Allergy And Infectious Diseases2001–2008
Phase II Trial Of Moxifloxacin For TBFood And Drug Administration2006–2007
Administrative CoreNational Institute Of Allergy And Infectious Diseases2005
ABC Training Grant For RIO DE Janeiro IcidrFogarty International Center2000–2004
Trial Of Rifapentine And Isoniazid Therapy For TBNational Center For Research Resources2000–2002
Improving Medication Adherence Among HIV Infected PatientsNational Center For Research Resources1997–2002
Clinical Training In HIVNational Institute Of Allergy And Infectious Diseases1992–2001
Nasopharyngeal Carriage Of Pathogenic Bacteria In An HIV+ PopulationNational Center For Research Resources1999
Adherence To TB Preventive Therapy In Drug UsersNational Institute On Drug Abuse1994–1997
Outcomes Of Pharmaceutical Therapy Of HIV DiseaseAgency For Healthcare Research And Quality1993–1994